Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database

Journal of Urology

Volumn 179, Issue 5, 2008, Pages 1785-1790

  Hamilton, Robert J ^a,b,c   Aronson, William J ^d   Terris, Martha K ^g   Kane, Christopher J ^e   Presti Jr , Joseph C ^f   Amling, Christopher L ^h   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h Alabama   (United States)

Author keywords

local; neoplasm recurrence; prostate; prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SEMINAL VESICLE; TREATMENT OUTCOME;

HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 41749121190     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.01.040     Document Type: Article

References (20)

1. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
2. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376
3. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
4. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572
5. Stephenson A.J., Shariat S.F., Zelefsky M.J., Kattan M.W., Butler E.B., Teh B.S., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325
6. Freedland S.J., Amling C.L., Dorey F., Kane C.J., Presti Jr. J.C., Terris M.K., et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60 (2002) 670
7. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
8. Freedland S.J., Aronson W., Presti Jr. J.C., Kane C.J., Terris M.K., Elashoff D., et al. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3?. Results from the SEARCH database. J Urol 169 (2003) 2142
9. American Cancer Society Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta
10. Cooperberg M.R., Grossfeld G.D., Lubeck D.P., and Carroll P.R. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95 (2003) 981
11. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
12. Zhou P., Chen M.H., McLeod D., Carroll P.R., Moul J.W., and D'Amico A.V. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992
13. Lee A.K., and D'Amico A.V. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23 (2005) 8192
14. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42
15. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141
16. Freedland S.J., and Platz E.A. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29 (2007) 88
17. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348 (2003) 1625
18. Freedland S.J., Aronson W.J., Kane C.J., Presti Jr. J.C., Amling C.L., Elashoff D., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004) 446
19. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25 (2007) 1765
20. Cordon-Cardo C., Kotsianti A., Verbel D.A., Teverovskiy M., Capodieci P., Hamann S., et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117 (2007) 1876